CX157

CX157
Clinical data
Routes of; administration	Oral
ATC code	none;
Legal status
Legal status	In general: uncontrolled;
Identifiers
	IUPAC name 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiine 10,10-dioxide;
CAS Number	205187-53-7 ;
PubChem CID	18687754;
ChemSpider	13701383 ;
UNII	O6L62LZJ0Q;
CompTox Dashboard (EPA)	DTXSID40174517 ;
Chemical and physical data
Formula	C14H8F4O4S
Molar mass	348.27 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES FC(F)(F)COc2cc3Oc1cc(F)ccc1S(=O)(=O)c3cc2;
	InChI InChI=1S/C14H8F4O4S/c15-8-1-3-12-10(5-8)22-11-6-9(21-7-14(16,17)18)2-4-13(11)23(12,19)20/h1-6H,7H2 ; Key:PDIMOTRDGUQMNY-UHFFFAOYSA-N ;
	(verify)

CX157 (proposed trade name TriRima, formerly Tyrima) is a selective and reversible inhibitor of MAO-A (RIMA).^[1] As of 2007 it was in phase II clinical trials for the treatment of depression.^[2] In 2013, work on the drug was terminated.[1]

References

^ Fielding R, Mielach F, Free J, Pande A (2007). Pharmacokinetics and oral bioavailability of CX157, a reversible selective MAO-A inhibitor, in primates (PDF). 2007 AAPS Annual Meeting & Exposition. Archived from the original (PDF) on 2011-05-26. Retrieved 2009-06-14.
^ Clinical trial number NCT00739908} for "A Study of CX157 (TriRima) for the Treatment of Depression (CX157-200)" at ClinicalTrials.gov

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.